Akari Therapeutics (AKTX) Operating Expenses (2014 - 2026)

Akari Therapeutics has disclosed Operating Expenses across 9 years of filings, most recently posting $15.8 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $15.8 million, up 347.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.3 million (down 80.41% YoY), and the FY2025 annual result was $17.3 million, down 20.18% from the prior year.
• Operating Expenses came in at $15.8 million for Q1 2026 at Akari Therapeutics, up from $3.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $112.0 million in Q4 2024 to a low of $2.2 million in Q3 2025.
• The 4-year median for Operating Expenses is $4.6 million (2023), against an average of $13.2 million.
• Across the five-year window, Operating Expenses soared 2100.12% in 2024 and sank 97.12% in 2025, its largest moves.
• Akari Therapeutics' Operating Expenses stood at $5.1 million in 2023, then jumped by 2100.12% to $112.0 million in 2024, then tumbled by 97.12% to $3.2 million in 2025, then surged by 388.32% to $15.8 million in 2026.
• The last three Operating Expenses figures came in at $15.8 million (Q1 2026), $3.2 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.